Search
EHA-PTHiT Hematology Mini Tutorial
Dates: April 12-13, 2021
Location: VIRTUAL
Chairs: I Hus (Poland), T Robak (Poland) & G Gaidano (Italy)
As a prelude to the full Tutorial planned for later this year, EHA and the Polish Society of Hematology and Transfusion (PTHiT) present a virtual 'mini…
First Hybrid HOPE meeting in Bangkok, Thailand - a report
Highlights of Past EHA (HOPE) Asia 2022
September 2-3, 2022 – Bangkok, Thailand
Meeting chairs
A Almeida, President, European Hematology Association (EHA)
G Gaidano, Chair Global Outreach Committee, European Hematology Association (EHA)
P Rojnuckarin, President, Thai Society of Hematology (TSH)
S Hongeng, Vice President, Thai Society…
EHA Research Conference 2022
Dates: October 17-20, 2022
Location: Palermo (Sicily), Italy
Chairs: Emmanuelle Passegué, Cristina Lo Celso, Mick Milsom, Meri Alberich Jorda, Antonella Fidanza, Jürg Schwaller, Thomas Mercher and Brian Huntly
Registration is closed
EHA is proud to announce the inaugural edition of the EHA Research Conference,…
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreMolecular Hematopoiesis Workshop
The Molecular Hematopoiesis Workshop at the EHA2024 Hybrid Congress is back!
OrganizersChair: Michael Milsom (Germany)
Co-chairs: Kim De Keersmaecker (Belgium), Elisa Laurenti (United Kingdom) & Britta Will (United States)
The full workshop program is available below
Session 1: Signalling and metabolism
Session 2: Gene regulation
Session…
Targeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- »